Recent advance in the discovery of allosteric inhibitors binding to the AMP site of fructose-1,6-bisphosphatase / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1291-1300, 2011.
Article
in Chinese
| WPRIM
| ID: wpr-232995
ABSTRACT
Fructose-1, 6-bisphosphatase (FBPase), a rate-limiting enzyme involved in the pathway of gluconeogenesis, can catalyze the hydrolysis of fructose-1, 6-bisphosphate to fructose-6-phosphate. Upon inhibiting the activity of FBPase, the production of endogenous glucose can be decreased and the level of blood glucose lowered. Therefore, inhibitors of FBPase are expected to be novel potential therapeutics for the treatment of type II diabetes. Recent research efforts were reviewed in the field of developing allosteric inhibitors interacting with the AMP binding site of FBPase.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Binding Sites
/
Blood
/
Blood Glucose
/
Adenosine Monophosphate
/
Chemistry
/
Fructose-Bisphosphatase
/
Diabetes Mellitus, Type 2
/
Enzyme Inhibitors
/
Allosteric Site
Limits:
Animals
/
Humans
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS